The vaccine committee in Germany has recommended that the AstraZeneca-Oxford vaccine should only be given to those under the age of 65, reported Economic Times.

Germany’s Standing Vaccine Commission has cited “insufficient data currently available to ascertain how effective the vaccination is above 65 years”, according to a report in Financial Times.

Speaking of India, a health expert told ET,

Responding to a query, AstraZeneca said, “Reports that the AstraZeneca/Oxford vaccine efficacy is low in adults over 65 years is not an accurate reflection of the totality of the data.”

However, CEO Pascal Soirot had said previously that it was fine if some countries, out of caution, use its vaccine for the younger group.

“The most recent Lancet publication has demonstrated that older adults showed strong immune responses to the vaccine, with 100% of older adults generating spike-specific antibodies after the second dose,” the company said.

(With inputs from Economic Times)